SAT0262 Comparison of Serum Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis after Treatment with Biologic Agents for 24 Weeks
Authors: Y. Hattori, A. Kaneko, D. Kida, N. Takahashi, H. Ishikawa, H. Kanda, T. Sato, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Matrix metalloproteinase-3 (MMP-3) is an enzyme produced by synoviocytes, and is a marker of synovitis that gives a more direct indication of actual joint destruction than either C-reactive protein (CRP) in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> Our aim in this study is to investigate the impact of the trend of serum MMP-3 and CRP during the treatment Adalimumab (ADA), Tocilizumab (TCZ), and Abatacept (ABT) in RA patients. <h3>Methods</h3> Among 672 patients with active RA (DAS28-CRP≥2.7) who were recruited in TBCR (Tsurumai Biologics Communication Registry), 303 patients were received ADA (40mg subcutaneously every other week) therapy, 124 patients were received TCZ (8 mg/kg every 4 weeks) therapy, and 245 patients were received ABT therapy (500mg for&lt;60 kg; 750 mg for 60 kg-100 kg; and 1 gram for&gt;100 kg infusion at week 0, 2, 4 and every 4 weeks). DAS28-CRP remission (DAS28-CRP&lt;2.3) rates at 24 weeks were 35% (73/210) for ADA therapy, 24% (30/124) for TCZ therapy, and 19% (39/201) for ABT therapy. We analyzed 142 patients who had DAS28-CRP remission at 24 weeks, consisting of 73 patients in ADA group, 30 patients in TCZ group, and 39 patients in ABT group, respectively. We compared the % change in serum MMP-3 and CRP levels from first administration to 24 weeks in 3 groups. <h3>Results</h3> While there was significant baseline difference in age, methotrexate (MTX) use and dose in 3 groups, there was no significant baseline difference in serum MMP-3 and CRP levels in 3 groups (Table). DAS28-CRP decreased similarly over the course of 24 weeks in 3 groups (Fig. 1). The % change in serum MMP-3 levels at 12, and 24 weeks was significantly greater in the ADA group than in the ABT group. ADA group is higher than TCZ group in the % change in serum MMP-3 levels over the course of 24 weeks. There was no difference in the % change in serum MMP-3 levels between the TCZ group and ABT group over the course of 24 weeks (Fig. 2a). The % change in CRP levels at 4 weeks was significantly greater in the ADA group than in the ABT group. However, there was no difference in the % change in CRP levels at 12, and 24 weeks between the ADA group and the ABT group. There was no difference in the % change in CRP levels between the ADA group and the TCZ group, the TCZ group and ABT group at 12 and 24 weeks (Fig. 2b). <h3>Conclusions</h3> ADA showed improvements in serum MMP-3 levels from an early stage in 24 weeks in a comparison with ABT. ADA can suppress synovitis and therefore the progression of joint destruction by strongly inhibiting MMP-3 when it is administered from an early stage. <h3>Disclosure of Interest</h3> Y. Hattori: None declared, A. Kaneko: None declared, A. Kaneko: None declared, D. Kida: None declared, D. Kida: None declared, N. Takahashi: None declared, N. Takahashi: None declared, H. Ishikawa: None declared, H. Ishikawa: None declared, H. Kanda: None declared, H. Kanda: None declared, T. Sato: None declared, T. Sato: None declared, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2074